For the DoxyPEP protocol itself — dosing, timing, the dairy rule, the esophagus risk, sun sensitivity, and the decision matrix for when to use it — read DoxyPEP: The Morning After Pill for Bacteria first. This guide covers the European-specific picture: why European medicine is cautious, where it's actually available, and how to navigate the gap between the evidence and official guidance.

The Evidence

The landmark US DoxyPEP study demonstrated compelling results:

  • 87% reduction in syphilis cases
  • 88% reduction in chlamydia cases
  • 55% reduction in gonorrhea cases

These findings prompted the US CDC to formally endorse DoxyPEP in 2023, making it official guidance for guys who have sex with guys with recent STI history or at high behavioural risk.

Current European Status

Unlike the United States, DoxyPEP is not officially recommended by most major European health authorities, including ECDC (European Centre for Disease Prevention and Control), national health ministries, or major sexual health organisations. The contrast is stark.

Why Europe Is Cautious

The resistance is rooted in legitimate scientific concern: antibiotic resistance. European healthcare systems — particularly in Nordic countries, Germany, and the Netherlands — maintain stricter frameworks around antibiotic prescribing. The concern is that normalising post-exposure antibiotic use, even short-course doxycycline, could accelerate resistance patterns.

This is not irrational caution. Antibiotic resistance is a genuine public health threat, and Europe's historical antibiotic stewardship has kept many organisms susceptible where they've become resistant in the US.

Where It's Actually Available

  • United Kingdom: The most progressive European country on this. Sexual health clinics in London, Manchester, and other major cities have begun offering DoxyPEP, particularly for those with recent STI diagnoses or high-risk exposure.
  • Ireland: Follows the general EU cautious position. Not officially recommended; some sympathetic specialists at the GUIDE Clinic (Dublin) may discuss it. Access requires navigating the same gap between evidence and guidelines as elsewhere in Europe.
  • France: Limited pilot programmes exist in some Paris clinics; remains experimental and not widely available.
  • Germany, Netherlands, Nordic countries: Largely resistant. Most sexual health specialists will not prescribe it routinely, and health insurance typically won't cover it.
  • Southern/Eastern Europe: Minimal access; generally requires private practice doctors.

How to Get It (Practical Reality)

Getting DoxyPEP in most of Europe requires navigating the gap between what the science shows and what official guidelines allow.

  • Contact sexual health/GUM clinics in your area, particularly in major cities. Some sympathetic specialists will prescribe it.
  • Private doctors with sexual health expertise are more likely to prescribe than public healthcare providers.
  • Some people access doxycycline through other prescriptions — for acne or travel malaria prophylaxis. We're simply noting that this happens.
  • Cost of doxycycline: roughly €10–20 for a box of tablets. Once you have a prescription, it's very affordable.

The Resistance Debate: Both Sides

The harm-reduction argument: If 70–90% of gay and bisexual men don't use condoms consistently and syphilis rates are climbing 30–50% year-over-year in major European cities, DoxyPEP could prevent substantial morbidity. The resistance concern may be theoretical if use is targeted to high-risk individuals.

The resistance argument: Europe's antibiotic stewardship has kept resistance rates lower than the US. Normalising post-exposure antibiotic use could tip epidemiology in the wrong direction. Better to invest in testing and vaccination.

Both perspectives contain truth. This is not a settled debate.

What DoxyPEP Does NOT Do

  • Does NOT prevent HIV — that's PrEP's function.
  • Does NOT protect against HPV or Hepatitis — vaccines cover those.
  • Does NOT replace regular testing — quarterly three-site testing is still required.
  • Does NOT prevent future infections — it only reduces risk after a specific exposure.

The Bottom Line

DoxyPEP is a legitimate harm-reduction tool with strong evidence. Europe's caution is not unfounded, but the syphilis and gonorrhea epidemics in gay male communities are real. If your doctor will prescribe it and you understand it doesn't replace testing or PrEP, it's a reasonable addition to a broader prevention strategy.

Related: